[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335802-105":59,"doc-detail-335802-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-classification-of-endometrial-cancers-using-an-integrative-dna-sequencing-panel","Molecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel","","Adoption of molecular classification for endometrial cancer into routine clinical practice is hindered by the complexity of coordinating multiple assays. This study develops a simplified molecular technique that classifies endometrial cancers into four subgroups using a custom targeted next-generation sequencing panel. Newly diagnosed patients from Ontario cancer centres were prospectively recruited and 181 tumours were sequenced, with variant pathogenicity assessed and clinicopathologic outcomes analyzed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-classification-of-endometrial-cancers-using-an-integrative-dna-sequencing-panel/335802/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-classification-of-endometrial-cancers-using-an-integrative-dna-sequencing-panel/335802.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the goal of the study on endometrial cancer molecular classification?","Question",{"text":112,"@type":113},"To develop a simplified molecular technique that classifies endometrial cancers into four subgroups using a custom targeted sequencing panel, enabling implementation in clinical practice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients and samples handled in the study?",{"text":117,"@type":113},"Patients with newly diagnosed endometrial cancers were prospectively recruited from three cancer centres in Ontario. Using the panel, 181 tumours were sequenced and variants were analyzed for pathogenicity, with clinicopathologic information collected retrospectively.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main molecular subgroup results from the 181 cases?",{"text":121,"@type":113},"Eighty-six cases (48%) were mismatch repair deficient, including MLH1 promoter methylation and pathogenic MMR gene variants. Single-classifier results included POLEmut (1.8%), TP53 mutations (9%), and NSMP (37%), with additional cases showing more than one molecular-classifying feature.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335802,1790217161,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Journal of  \nSurgical Oncology  \nRESEARCH ARTICLE   \nMolecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel  \nSoyoun R. Kim1,2  | Leslie Oldfield3 | Raymond H. Kim4,5,6,7 | Osvaldo Espin‐Garcia8 | Kathy Han9 | Danielle Vicus2, 10 | Lua Eiriksson11 | Alicia Tone1 | Aaron Pollett12 | Matthew Cesari12 | Blaise Clarke12 | Marcus Q. Bernardini1,2  | Trevor J. Pugh3,7 | Sarah E. Ferguson1,2  \n1Division of Gynecologic Oncology, Princess Margaret Cancer Centre, Sinai Health Systems, University Health Network, Toronto, Ontario, Canada | 2Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada | 3Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada | 4Fred A Litwin Family Centre for Genetic Medicine, University Health Network, Toronto, Ontario, Canada | 5Zane Cohen Centre for Digestive Diseases, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Ontario, Canada | 6Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Sinai Health Systems, University Health Network, Toronto, Ontario, Canada | 7Ontario Institute for Cancer Research, University Health Network, Toronto, Ontario, Canada | 8Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada | 9Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada | 10Division of Gynecologic Oncology, Odette Cancer Centre, Toronto, Ontario, Canada | 11Division of Gynecologic Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada | 12Department of Laboratory  \nMedicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Correspondence: Soyoun R. Kim ([Rachelsoyoun.kim@uhn.ca](Rachelsoyoun.kim@uhn.ca))  \nReceived: 6 June 2024 | Revised: 8 August 2024 | Accepted: 12 October 2024  \nFunding: This study was supported by funding from the Hold'em for Life Clinician Scientist Award and Violet River Award in Gynecology from the Department of Obstetrics and Gynecology, University of Toronto.  \nKeywords: endometrial cancer | molecular classification | molecular subtype | next‐generation sequencing | panel  \nABSTRACT  \nBackground and Objectives: Adoption of molecular classification in endometrial cancer (EC) into clinical practice remains challenging due to complexity in coordination of multiple assays. We aimed to develop a simple molecular technique to classify ECs into four subgroups using our custom‐designed targeted sequencing panel.  \nMethods: Patients with newly diagnosed ECs were prospectively recruited from three cancer centres in Ontario, Canada. Using our panel, 181 ECs were sequenced. Variants were analysed for pathogenicity and clinicopathologic information was collected through medical records retrospectively.  \nResults: Of 181, 86 (48%) were mismatch repair deficient (MMRd), of which 62 (72%) harboured MLH1 promoter methylation and 24 (28%) had pathogenic variants in MMR genes. Of single classifiers, three (1.8%) had pathogenic POLE (POLEmut), 15 (9%) had TP53 mutations (p53abn) and 61 (37%) had no specific molecular profile subtype (NSMP) . Sixteen (9%) had more than one molecular classifying feature, with eight (4%) MMRd‐p53abn, six (3%) POLEmut‐MMRd, one (0.5%) POLEmut‐MMRd‐ p53abn and one (0.5%) POLEmut‐p53abn. When MMRd group was further subclassified according to mechanism of MMR loss, MLH1 promoter methylated group had worse outcomes than those with somatic MMR pathogenic variants.  \nConclusions: Our panel can classify ECs into four subgroups through a simplified process and can be implemented reflexively in clinical practice.  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2024 The Author(","cbCaibzYnXnxCOvT","https://ap.wps.com/l/cbCaibzYnXnxCOvT","pdf",541920,"English","# Abstract\n## Background and Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the goal of the study on endometrial cancer molecular classification?\",\"answer\":\"To develop a simplified molecular technique that classifies endometrial cancers into four subgroups using a custom targeted sequencing panel, enabling implementation in clinical practice.\"},{\"question\":\"How were patients and samples handled in the study?\",\"answer\":\"Patients with newly diagnosed endometrial cancers were prospectively recruited from three cancer centres in Ontario. Using the panel, 181 tumours were sequenced and variants were analyzed for pathogenicity, with clinicopathologic information collected retrospectively.\"},{\"question\":\"What were the main molecular subgroup results from the 181 cases?\",\"answer\":\"Eighty-six cases (48%) were mismatch repair deficient, including MLH1 promoter methylation and pathogenic MMR gene variants. Single-classifier results included POLEmut (1.8%), TP53 mutations (9%), and NSMP (37%), with additional cases showing more than one molecular-classifying feature.\"}]","Molecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel | PDF",1790012379]